EpiCept Corporation and GNI Partner to Develop Anti-Viral Hepatitis Drug in Asia

Published: Jul 17, 2008

TOKYO & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News:

GNI Ltd, a leading biopharmaceutical company in Japan and China, and EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT), a US-based specialty pharmaceutical company, announced today that they have reached agreement to develop a new therapeutic drug, EP1013, in Asia, Australia, and New Zealand, for late-stage viral infection-induced hepatitis. EpiCept will retain the rights in the rest of the world. GNI’s wholly owned subsidiary, Shanghai Genomics, will start preparation for pre-IND and clinical development in China immediately.

Back to news